Summit launches Phase III ivonescimab trial in Stage III lung cancer
+1 new source since this summary was written
Summit Therapeutics announced on November 18, 2026, that it had begun HARMONi-10, a global Phase III study of ivonescimab versus durvalumab in locally advanced, unresectable Stage III non-small cell lung cancer. The trial will enroll patients who have not progressed after platinum-based concurrent chemoradiation, with progression-free survival as its primary endpoint. Global site activations are expected in Q4 2026, and ivonescimab is not approved in the United States or Europe.
Why it matters
The trial extends Summit's late-stage development program into a locally advanced lung-cancer setting where durvalumab is an established treatment after chemoradiation. Because ivonescimab remains investigational in the United States and Europe, the announcement does not represent an immediate commercial approval or revenue event.
Key facts
- 1HARMONi-10 is a global Phase III trial comparing ivonescimab with durvalumab in locally advanced, unresectable Stage III non-small cell lung cancer. investing.com
- 2Progression-free survival is the trial's primary endpoint, and global site activations are expected in Q4 2026. investing.com
- 3Ivonescimab lacks regulatory approval in Summit's license territories, including the United States and Europe, but received marketing authorization in China in May 2024. investing.com
- 4Over 5,000 patients have received ivonescimab in global clinical studies and over 100,000 have received it commercially in China. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.